Control of AA amyloidosis complicating Crohn's disease: A clinico-pathological study

European Journal of Clinical Investigation

Volumn 43, Issue 3, 2013, Pages 292-301

  Denis, Marie A ^a   Cosyns, Jean Pierre ^a   Persu, Alexandre ^a   Dewit, Olivier ^a   de Galocsy, Chantal ^b   Hoang, Pierre ^a   Maldague, Philippe ^c   Wallemacq, Pierre ^a   Zerbib, Frank ^d   Fiasse, René ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b IRIS   (Belgium)

^c Hôpital St Luc   (Belgium)

^d HÔPITAL SAINT ANDRÉ   (France)

Author keywords

AA amyloidosis; Anti TNF agents; Crohn's disease; Immunosuppressive drugs; Inflammatory bowel disease; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; COLCHICINE; INFLIXIMAB; SERUM AMYLOID A; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; CROHN DISEASE; DEATH; DISEASE COURSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AMYLOIDOSIS; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84874000863     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12045     Document Type: Article

References (34)

1. Cohen H, Fishman AP. Regional enteritis and amyloidosis. Gastroenterology 1949;12:502-8.
2. Greenstein AJ, Sachar DB, Nannan Panday AK, Dikman SH, Meyers S, Heirmann T et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine 1992;71:261-70.
3. Glenner GG. Amyloid deposits and amyloidosis. The β-Fibrilloses. N Engl J Med 1980;302:1283-92.
4. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
5. Waldenström H. On the formation and disappearance of amyloid in man. Acta chir Scandinav 1928;63:479-530.
6. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71.
7. Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
9. Morel-Maroger LM, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976;6:79-118.
10. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986;27:809-13.
11. De Beer FC, Fagan EA, Hugues GRV, Mallya RK, Lanham JG, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231-7.
12. Freeman HJ. Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. Can J Gastroenterol 2007;21:363-6.
13. Verbanck J, Lameire N, Praet M, Ringoir S, Elewaut A, Barbier F. Renal amyloidosis as complication of Crohn's disease. Acta Clin Belg 1979;34:6-13.
14. Gries E, Singer MV, Goebell H. Amyloidose bei Morbus Crohn. Fallvorstellung und übersicht über die literature. Med Klin 1989;84:65-71.
15. Tovbin D, Kachko L, Hilzenrat N. Severe interstitial nephritis in a patient with renal amyloidosis and exacerbation of Crohn's disease. Clin Nephr 2000;53:147-51.
16. Larvol L, Cervoni J-P, Besnier M, Dupouet L, Beaufils H, Clauvel J-P et al. Syndrome néphrotique réversible au cours d'une maladie de Crohn compliquée d'amylose rénale. Gastroenterol Clin Biol 1998;22:639-41.
17. Mandelstam P, Simmons De, Mitchell B. Regression of amyloid in Crohn's disease after bowel resection. A 19-year follow-up. J Clin Gastroenterol 1989;11:324-6.
18. Leiper K, Howse MLP, Bell GM. Resolution of nephrotic syndrome caused by amyloidosis following surgery for Crohn's disease. Hospital Medicine 2000;61:802-3.
19. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571.
20. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olivé A, de Haro M et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6.
21. Bosca MM, Perez-Baylach CM, Solis MA, Anton R, Mayordomo E, Pons S et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006;55:294-5.
22. Iiuzuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006;55:744-5.
23. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis 2008;14:431-2.
24. Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B et al. Benefit of anti-TNFα treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003;62:368-9.
25. Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008;12:1738-44.
26. Regueiro M, Schraut W, Baidoo L, Kipp KE, Sepulveda AR, Pesci M et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-50.
27. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New Engl J Med 1986;314:1001-5.
28. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres 2000;14:477-98.
29. Garrido A, Guerrero Igea FJ, Hierro Gullmain C, Ruiz Lupianez E, Palomo Gila S. Respuesta favorable a la colchicina en la amiloidosis secundaria a la enfermedad inflamatoria intestinal [Good response to colchicine in amyloidosis secondary to inflammatory bowel disease]. Gastroenterol Hepatol 2001;24:196-8.
30. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-7.
31. Lovat LB, Madhoo S, Pepys MB, Hawkins PH. Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology 1997;112:1362-5.
32. Maury CP. Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci (Lond) 1985;68:233-8.
33. Sack GH. Serum amyloid A (SAA) gene variations in familial Mediterranean fever. Mol Biol Med 1988;5:61-7.
34. Obici L, Raimondi S, Lavatellli F, Bellotti V, Merlini G. Susceptibility to Amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435-40.